Columbia University 3D Printing Hair

Dr. Angela Christiano and her team from Columbia University are back in the headlines for a range of new hair growth discoveries, one of them being progress on the 3D printing of hair follicles.

3D Follicles In The Dish

It’s no secret that Angela Christiano has been studying the biology of hair follicles for decades. She has studied hair follicle genetics, immune response in hair follicles, and dermal papilla cell culturing in an effort to discover new cures for hair loss. The bulk of her research in DP cell culturing has been done alongside Dr. Colin Jahoda of Durham University who is known as the “godfather” of hair follicle cell research. Over the past several years, Jahoda and Christiano have even been working on a biotech company to commercialize successful hair follicle research which I will get into later in this article. One of the greatest hurdles to overcome in hair follicle cloning has been creating an environment for dermal papilla cells to grow in which mimicked the natural human scalp biology. The below video explains how Christiano and her team were able to successfully create the right environment for hair follicles to grow in.

According to the publication from Columbia University, Christiano and team used 3D printing to create a more optimal environment for growing hair follicles. The process is described in detail as follows:

“The researchers used 3D printing to create plastic molds with long, thin extensions only half a millimeter wide.

After human skin was engineered to grow around the mold, hair follicle cells from human volunteers were placed into the deep wells and topped by cells that produce keratin. The cells were fed a cocktail of growth factors spiked with ingredients, including JAK inhibitors, that the lab has found stimulates hair growth. 

After three weeks, human hair follicles appeared and started creating hair.”

Engineered Hair Follicle Research. Credit: Angela Christiano / Columbia University Irving Medical Center

It’s interesting to note in that quote the hair follicles were not only feed growth factors which are necessary for the proper biological formation of hair follicles, but they were also fed JAK inhibitors which we know from a recent Follicle Thought Aclaris article have been found to stimulate hair growth through the TREM2+ mechanism

After discovering years ago that JAK inhibitors had the capability of activating the growth or “anagen” phase of a hair follicle, Christiano and researches delved further into the JAK-STAT pathway to find out exactly how it could manipulate the hair follicle growth cycle. The outcome of that research was the discovery of a new type of immune cell called a trichophage. These trichophages produce a substance called Oncostatin M which keeps hair follicles in a resting phase. If the production of Oncostatin M is blocked, the hair follicle begins to grow again. Christiano and her team are undoubtedly looking for new small molecule drugs and antibodies which could block the production of Oncostatin M in hair follicles. 

The Rapunzel Company

The next most important step for Christiano is to now take this discovery into the clinic for human use. It seems she is well prepared to do so, as she has been working on her private hair follicle cloning company Rapunzel Biosciences for the past several years. The project is a culmination of the research that Christiano has done alongside Dr. Colin Jahoda and the two of them account for some of the most advanced hair follicle cell culturing research in the world.

The website for Rapunzel Biosciences showed up online earlier this year around February and that seems to coincide with a research paper that Christiano and Jahoda published on December 13 2018 titled: “Tissue engineering of human hair follicles using a biomimetic developmental approach.”

In the latest article from Columbia, it mentions that the new 3D printing method needs to be optimized, though “engineered human hair follicles created in this way could generate an unlimited source of new hair follicles for patients undergoing robotic hair restoration surgery.” Christiano describes this method as creating a “hair farm”, or a grid of hair follicles that have the correct shape and biology which could be transplanted into human scalps.

Another exciting aspect of this research is the ability to screen new drugs on hair follicles created in a petri dish. Christiano thinks this approach will be appealing and useful for pharmaceutical companies. New compounds and re-purposed “old compounds” could be applied to the engineered hair follicles and then observed for hair growth. The follicles that obtained hair growth from the compounds could further be observed to determine the biological mechanism within the hair follicle which caused the hair growth. Exciting stuff.

14 Comments

  1. Greg on June 26, 2019 at 12:43 pm

    Admin, so is it Japan vs the US now? Is this something to get excited over or are these people still preclinical and a ways away from commercialization? Thanks



    • Follicle Thought on June 26, 2019 at 12:50 pm

      You know, I’d say they are a ways from commercialization realistically however Japan is a ways from commercialization too. That has to be the presumed situation until they announce news otherwise.



  2. Michael Lazzari on June 26, 2019 at 5:54 pm

    I really needed this today. Thanks



    • Follicle Thought on June 26, 2019 at 8:28 pm

      No problem



  3. vlmp on June 27, 2019 at 12:35 am

    Pretty exciting staff admin!
    So from what i presume a phase 1 for safety has not begun.Right?



    • Follicle Thought on June 27, 2019 at 9:29 am

      Not yet, the technology still has to be optimized as they say. So, it’s going to take a little bit of time before any phase 1.



  4. Jonathan Weaver on June 27, 2019 at 12:34 pm

    If the phase 1 start in 2021, that means commercial release in 2028 at best. Better concentrate on treatments which will be released in 2020-2021 like Samumed or Histogen.



    • Follicle Thought on June 27, 2019 at 2:13 pm

      I like this point.

      Samumed, Histogen, Shiseido, and even Follica are the nearest term solutions.



    • Alan J on June 30, 2019 at 5:05 am

      Impossible to say. At least with so much competition there is a real incentive to get to the market as soon as possible. Japan and the UK appear to have more relaxed laws which could help speed things up. e.g. in the UK, subject to certain conditions it is possible to make new treatments available as long as they are not advertised, and they are licensed.



  5. Follicle Thought on June 27, 2019 at 5:26 pm

    Which do people think is going to clinical trials first, Rapunzel or Organ Tech/Tsuji?



    • Alan J on June 30, 2019 at 5:01 am

      I thought there was a strong indication at end of last year that Tsuji was still on track for human clinical trials by 2020, or at least during 2020? Also, you mentioned recently that you are going to cover a company that seems to be ahead of the game. Did you mean Rapunzel or Stemson, or is there something else to look forward to? Thanks as ever for all your work.



      • Follicle Thought on June 30, 2019 at 11:16 am

        The thing about these companies is that they go silent for a year to a year and a half, and then we get an update. After a year-year and a half of waiting for update we get to find out whether they made progress or if they are basically in the same spot they were a year ago and they need to do much more work to move forward. Organ Tech/Tsuji is in this boat. It all depends on what has happened behind the scenes for them since last year and the truth is only they know what’s going on. Shiseido is another example.



  6. Alan J. Bauman, MD, ABHRS (@DrAlanBauman) on June 28, 2019 at 8:18 am

    Am I missing something, what’s new? I seem to remember the latest study was published last year.



    • Follicle Thought on June 28, 2019 at 9:51 am

      Surely they have continued r&d since December, no?



Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.